J. Safra Sarasin Holding AG decreased its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 13.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 20,110 shares of the medical research company's stock after selling 3,119 shares during the quarter. J. Safra Sarasin Holding AG's holdings in IQVIA were worth $3,952,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Synergy Asset Management LLC acquired a new stake in shares of IQVIA during the 4th quarter worth approximately $33,000. GKV Capital Management Co. Inc. acquired a new stake in shares of IQVIA during the fourth quarter worth $39,000. Lee Danner & Bass Inc. bought a new stake in IQVIA in the fourth quarter valued at about $44,000. Zions Bancorporation N.A. grew its position in shares of IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock worth $47,000 after buying an additional 85 shares during the period. Finally, Versant Capital Management Inc increased its stake in shares of IQVIA by 46.0% in the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock valued at $58,000 after acquiring an additional 93 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.
Wall Street Analysts Forecast Growth
A number of analysts recently commented on IQV shares. HSBC cut shares of IQVIA from a "buy" rating to a "hold" rating and lowered their price objective for the company from $260.00 to $160.00 in a research report on Friday. Citigroup dropped their price target on IQVIA from $225.00 to $210.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. Robert W. Baird cut their price target on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 21st. Stifel Nicolaus lowered their price objective on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Finally, Barclays reaffirmed an "equal weight" rating and issued a $170.00 price objective (down from $235.00) on shares of IQVIA in a research report on Thursday, April 10th. Seven investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, IQVIA currently has a consensus rating of "Moderate Buy" and a consensus price target of $237.62.
Check Out Our Latest Report on IQV
IQVIA Stock Performance
Shares of NYSE:IQV traded down $0.30 on Friday, hitting $150.38. The company had a trading volume of 1,333,062 shares, compared to its average volume of 1,419,099. The stock has a market cap of $26.51 billion, a price-to-earnings ratio of 20.05, a P/E/G ratio of 1.99 and a beta of 1.46. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 1-year low of $135.97 and a 1-year high of $252.88. The stock has a 50 day moving average price of $172.46 and a 200 day moving average price of $194.57.
IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.
IQVIA Profile
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Further Reading
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
